Ma WJ, Wang X, Yan WT, Zhou ZG, Pan ZZ, Chen G, Zhang RX. Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer. World J Gastroenterol 2018; 24(20): 2181-2190 [PMID: 29853736 DOI: 10.3748/wjg.v24.i20.2181]
Corresponding Author of This Article
Rong-Xin Zhang, MD, Attending Doctor, Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Dongfeng East Road No. 651, Guangdong 510060, Guangzhou Province, China. zhangrx@sysucc.org.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 28, 2018; 24(20): 2181-2190 Published online May 28, 2018. doi: 10.3748/wjg.v24.i20.2181
Table 1 Correlation of cytoplasmic indoleamine-2,3-dioxygenase 1 expression with colorectal cancer clinicopathologic parameters
Characteristic
Total
Low IDO1
High IDO1
P-value
Sex
0.074
Male
52
22 (42.3)
30 (57.7)
Female
43
27 (62.8)
16 (37.2)
Age in yr
0.65
≥ 60
30
17 (56.7)
13 (43.3)
< 60
65
32 (49.2)
33 (50.8)
Cancers
0.93
Colon
46
24 (52.2)
22 (47.8)
Rectum
49
25 (51.0)
24 (49.0)
BMI
0.16
≥ 25
20
7 (35.0)
13 (65.0)
< 25
75
42 (56.0)
33 (44.0)
Tumor differentiation
0.47
Moderate and poor
78
42 (54.5)
35 (45.5)
Well
17
7 (41.2)
10 (58.8)
Colon cancer stage
0.52
3
20
12 (60.0)
8 (40.0)
2
26
12 (46.2)
14 (53.8)
T stage
0.69
4
29
14 (48.3)
15 (51.7)
2/3
17
10 (58.8)
7 (41.2)
N stage
0.96
1/2
20
11 (55.0)
9 (45.0)
0
26
13 (50.0)
13 (50.0)
Rectum cancer stage
0.67
3
24
11(45.8)
13 (54.2)
2
25
14 (46.0)
11 (44.0)
T stage
0.68
4
22
12 (55.6)
10 (45.4)
2/3
27
12 (44.4)
15 (55.6)
N stage
0.88
1/2
24
12 (50.0)
12 (50.0)
0
25
13 (52.0)
12 (48.0)
CEA in ng/mL
0.45
> 5
42
24 (57.1)
18 (42.9)
≤ 5
53
25 (47.2)
28 (42.8)
CA19-9 in U/mL
0.22
> 37
17
6 (35.3)
11 (64.7)
≤ 37
78
43 (55.1)
35 (44.9)
CD3 TILs
0.27
High
36
22 (61.1)
14 (38.9)
Low
59
28 (47.5)
31 (42.5)
CD8 TILs
0.96
High
22
12 (54.5)
10 (45.5)
Low
73
38 (52.5)
35 (47.5)
COX2
0.92
High
48
26 (54.2)
22 (45.8)
Low
47
24 (51.1)
23 (48.9)
Treatment group
0.58
Celecoxib
44
25 (56.8)
19 (43.2)
Non-celecoxib
51
25 (49.0)
26 (51.0)
Table 2 Correlation of nuclear indoleamine-2,3-dioxygenase 1 expression with colorectal cancer clinicopathologic parameters
Characteristic
Total
Low IDO1
High IDO1
P-value
Sex
0.70
Male
51
39 (76.5)
12 (33.5)
Female
44
36 (81.8)
8 (19.2)
Age in yr
0.92
> 60
30
24 (80.0)
6 (20.0)
≤ 60
65
51 (78.5)
14 (21.5)
Cancers
0.52
Colon
46
38 (82.6)
18 (17.4)
Rectum
49
37 (75.5)
12 (24.5)
BMI
< 0.001
> 25
20
9 (45.0)
11 (55.0)
≤ 25
75
66 (88.0)
9 (12.0)
Tumor differentiation
0.87
Moderate and poor
78
60 (76.9)
18 (23.1)
Well
17
14 (82.3)
3 (17.7)
Conlon cancer stage
0.98
3
20
17 (85.0)
3 (15.0)
2
26
21 (80.8)
5 (19.2)
T stage
0.71
4
29
23 (19.3)
6 (20.7)
2/3
17
15 (88.2.)
2 (11.8)
N stage
0.98
1/2
20
16 (80.0)
4 (20.0)
0
26
22 (84.6)
4 (15.4)
Rectum cancer stage
0.44
3
24
17 (70.8)
7 (29.2)
2
25
21 (84.0)
4 (16.0)
T stage
0.94
4
22
16 (72.7)
6 (27.3)
2/3
27
21 (77.8)
6 (22.2)
N stage
0.28
1/2
24
16 (66.7)
8 (33.3)
0
25
21(84.0)
4 (16.0)
CEA in ng/mL
0.37
> 5
42
35 (83.3)
7 (16.7)
≤ 5
53
39 (73.6)
14 (26.4)
CA19-9 in U/mL
0.78
> 37
81
41 (50.6)
40 (49.4)
≤ 37
17
8 (47.1)
9 (52.9)
CD3 TILs
0.96
High
36
28 (77.8)
8 (22.2)
Low
59
47 (79.7)
12 (20.3)
CD8 TILs
0.26
High
22
15 (68.2)
7 (31.8)
Low
73
60 (82.2)
13 (17.8)
COX2
0.84
High
48
38 (79.2)
10 (20.8)
Low
47
37 (78.7)
10 (21.3)
Treatment group
0.16
Celecoxib
44
38 (86.4)
6 (13.6)
Non-celecoxib
51
37 (72.5)
14 (27.5)
Table 3 Univariate analysis of the correlation of clinicopathological parameters with overall survival in patients with colorectal carcinoma
HR
95%CI
P value
Sex, male vs female
0.750
0.399-1.411
0.37
Age in yr, ≤ 60 vs > 60
0.899
0.472-1.714
0.74
Cancer, colon vs rectum
1.279
0.712-2.296
0.41
BMI, > 25 vs ≤ 25
1.579
0.697-3.579
0.21
Tumor differentiation, moderate and poor vs well
2.798
1.373-5.702
0.039
Stage, 3 vs 2
1.003
0.534-1.882
0.99
T stage, T4 vs T2/3
1.418
0.755-2.664
0.27
N stage, N1/2 vs N0
1.005
0.536-1.887
0.99
CEA in ng/mL, > 5 vs ≤ 5
2.137
1.141-4.004
0.025
CA19-9 in U/mL, > 37 vs ≤ 37
1.262
0.547-2.911
0.56
CD3 TILs, high vs low
1.195
0.649-2.198
0.55
CD8 TILs, high vs low
2.096
0.975-4.504
0.018
Nuclear IDO1, high vs low
2.044
0.871-4.798
0.039
Cytoplasmic IDO1, high vs low
1.690
0.901-3.173
0.10
Nuclear and cytoplasmic IDO1, high vs low
2.044
0.871-4.798
0.039
COX2, high vs low
1.235
0.659-2.314
0.51
Nuclear IDO1/COX2, IV vs I/II/III
3.048
0.868-10.7
0.0049
Cytoplasmic IDO1/COX2, IV vs I/II/III
2.109
0.976-4.558
0.022
Treatment group, celecoxib vs non-celecoxib
0.943
0.489-1.826
0.86
Table 4 Multivariate analysis of the correlation of indoleamine-2,3-dioxygenase 1 with overall survival in patients with Colorectal cancer
HR
95%CI
P-value
Cytoplasmic IDO1 and COX2, IV vs I/II/III
2.218
1.011-4.48
0.047
Tumor differentiation, poor and moderate vs well
3.473
1.201-10.046
0.022
Table 5 Univariate analysis of the correlation of clinicopathological parameters with overall survival in CRC celecoxib subgroup
HR
95%CI
P value
Sex, male vs female
0.854
0.329-2.219
0.74
Age in yr, ≤ 60 vs > 60
1.249
0.432-3.609
0.70
Cancer, colon vs rectum
1.034
0.420-2.543
0.94
BMI, > 25 vs ≤ 25
1.328
0.351-5.020
0.71
Tumor differentiation, moderate and poor vs well
7.396
2.749-19.90
0.021
Stage, 3 vs 2
1.075
0.415-2.782
0.88
T stage, T4 vs T2/3
1.389
0.537-3.596
0.50
N stage, N1/2 vs N0
1.075
0.415-2.782
0.88
CEA in ng/mL, > 5 vs ≤ 5
1.934
0.743-5.033
0.21
CA19-9 in m/L, > 37 vs ≤ 37
1.551
0.431-5.575
0.43
CD3 TILs, high vs low
1.02
0.414-2.510
0.97
CD8 TILs, high vs low
2.821
0.774-10.29
0.026
Nuclear IDO1, high vs low
3.023
0.585-15.61
0.041
Cytoplasmic IDO1, high vs low
1.623
0.617-4.267
0.31
Nuclear and cytoplasmic IDO1, high vs low
3.023
0.585-15.61
0.041
COX2, high vs low
1.746
0.672-4.541
0.25
Nuclear IDO1/COX2, IV vs I/II/III
1.885
0.279-12.76
0.38
Cytoplasmic IDO1/COX2, IV vs I/II/III
2.740
0.764-9.831
0.038
Table 6 Multivariate analysis of the correlation of indoleamine-2,3-dioxygenase 1 with overall survival in Colorectal cancer celecoxib subgroup
HR
95%CI
P-value
Cytoplasmic IDO1 and COX2, IV vs I/II/III
3.210
1.074-9.590
0.037
Tumor differentiation, poor and moderate vs well
11.962
1.526-23.787
0.018
Citation: Ma WJ, Wang X, Yan WT, Zhou ZG, Pan ZZ, Chen G, Zhang RX. Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer. World J Gastroenterol 2018; 24(20): 2181-2190